ICOSLG Specific Neutra™ Antibody Products

Inducible T cell costimulator ligand (ICOSLG), also known as B7H and CD275, is a single-pass type I membrane protein. This protein is a ligand of ICOS, a T-cell-specific cell surface receptor. The ICOS-ICOSLG pathway has important clinical significance for the immune system.

Its Gene ID is 23308, OMIM ID is 605717, and UniProtKB ID is O75144.

ICOS-ICOSLG Signaling Pathway

Attracting cognate Tfh cells and engaging in T-B collaboration is critical for the differentiation of GC B cells. Here we list the role of the ICOS-ICOSL pathway under conditions with or without TCR engagement in Tfh migration and T-B collaboration.

Transient and repetitive ligation of the ICOS-ICOSL without TCR engagement functions as the following (Figure 1A):

• Induces transient actin remodeling, which involves programming and motility of T follicular helper (Tfh) cells.
• Facilitates cognate T-B conjugation and its entry into the germinal center (GC) of lymphoid organs to generate high-affinity antibodies.

Ligation of ICOS-ICOSL with TCR engagement in the TCR and peptide-MHC complex works as follows (Figure 1B):

• Facilitates CD40L externalization causing CD40 co-stimulation to GC-B cells.
• Increases translation of IL-4 mRNA and accurately delivers CD40L and IL-4 for effective selection of GC-B cell clones with high affinity for the internalized cognate antigens.

Fig.1 ICOS-ICOSLG signal transduction during Tfh migration and T-B collaboration.¹

Clinical Significance of ICOSLG

ICOS and ICOSLG are closely associated with various diseases, such as colorectal cancer, acute lymphoblastic leukemia, autoimmune diseases, immunodeficiency, and other inflammatory diseases. Therefore, ICOS-ICOSLG signaling is a promising biomarker and target for immunodiagnosis, prognosis, and therapy.

• In preclinical or clinical studies, the agonistic antibodies targeting the ICOS-ICOSLG pathway could induce tumor regression through the regulation of T-cell immunity. These antagonistic antibodies have been used for cancer treatment.
• The rationale study about this signal reveals that the ICOS-ICOSLG pathway may help improve vaccine prevention and immunotherapy treatment of immune disorder diseases and cancers.

Creative Biolabs offers a comprehensive range of high-quality anti-ICOSLG antibodies to assist research studies of our customers.

Reference

1. Panneton, Vincent.; et al. "Inducible T-cell co-stimulator: signaling mechanisms in T follicular helper cells and beyond." Immunological Reviews 291.1 (2019): 91-103.